In
Because of its success in various solid cancers, immunotherapy is the fastest growing treatment approach in oncology. However, clinical evidence is accumulating that immunotherapy often needs to be combined with other drug modalities to improve the long-term treatment outcome for patients.
Ovarian cancer kills more than 40.000 women in
IndiTreat[®], a Functional Precision Medicine test, will be able to measure the efficacy of both existing and novel immunotherapies alone or in combination with other cancer drugs thus providing an effective means to improve the overall outcome of ovarian cancer patients.
Jürgen Kupper, Managing Director, 2cureX GmbH says: "2cureX's efforts to expand the capabilities of IndiTreat[®] to guide treatment of cancer patients is critically dependent upon active collaborations with world class clinical institutions. It is therefore with excitement that we now can strengthen our year-long collaboration with UKE to finalize the IndiTreat[®] test for immunotherapy in ovarian cancer patients."
For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com
Certified Adviser:
Email: ca@skmg.se
Phone: +46 11 32 30 732
This information is information that
-------
About 2cureX
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumours that are similar to the patient's tumour and identifies the treatment that most effectively kills the patient's tumor. Immediately after the test, the patient can be offered the selected treatment.
IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in
IndiTreat® is presently being introduced into the European market through an Early Access Program.
The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.
The company is listed at the Nasdaq First North Growth Market in
https://news.cision.com/2curex/r/2curex--germany-receives-an-additional-grant-for-adapting-inditreat--to-guide-immunotherapy-of-ovari,c3082273
https://mb.cision.com/Main/16432/3082273/1225226.pdf
https://news.cision.com/2curex/i/uke,c2769750
https://news.cision.com/2curex/i/jurgen-kupper--2curex-gmbh,c2769754
(c) 2020 Cision. All rights reserved., source